Combination treatment for recurrent or hard-to-treat large b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has not responded to treatment or has returned. The goal is to see if this combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has a marker called CD20 on the cancer cells.
- You must be 18 or older and generally able to care for yourself (a doctor will check your activity level).
- Your lymphoma must have not improved, come back within a year of your first treatment, or returned after a second treatment or a stem cell transplant.
- You must have at least one area of lymphoma that shows up on a scan and is big enough to measure.
- You must not have serious heart, liver, or other organ problems, and your blood counts should be within safe limits (unless low counts are due to lymphoma).
- You must be willing to give written consent and follow the study rules, including using birth control if you can become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.